secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001645113-24-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure completes enrollment in Phase 3 TRIDENT trial for newly diagnosed glioblastoma; data expected 2026
--------------------------------------------------------------------------------

- Final patient enrolled in global Phase 3 TRIDENT trial (950 patients) evaluating Optune Gio concurrent with radiation + temozolomide for newly diagnosed GBM.
- Patients randomized to TTFields + TMZ + radiation vs TMZ + radiation for 6 weeks, then all receive standard care (TTFields + maintenance TMZ).
- Primary endpoint is overall survival; secondary endpoints include PFS, safety, quality of life, and radiological response.
- Top-line data from the trial is anticipated in 2026; enrollment began in December 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000004/0001645113-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000004/nvcr-20240109.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer